Sun Pharma
Search results
Cipla is a company that aims to care for life through its products and services in various therapeutic categories. Learn about its purpose, portfolio, latest news, investor relations, and social responsibility.
- About Us
Cipla is a leading pharmaceutical company that provides...
- Our Offerings
Over last 2 years, Cipla has been focusing towards...
- Investors
Cipla signs a non-exclusive patent license agreement with...
- Careers
Cipla India strongly recommends against potential...
- Media Centre
Cipla announces joint venture in the United States with...
- Corporate Social Responsibility
In true Cipla spirit, our employees spent 70,000+ hours of...
- Contact Us
Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg,...
- Our Therapies
The Cipla Palliative Care and Training Centre Pune was set...
- About Us
Cipla Limited (stylized as Cipla) is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and various other medical conditions.
Cipla is a global healthcare company that offers over 1,500 products across various therapeutic categories. Founded in 1935 by Dr. K.A. Hamied, Cipla has a purpose of Caring for Life and a history of innovation and social responsibility.
Cipla Share Price: Find the latest news on Cipla Stock Price. Get all the information on Cipla with historic price charts for NSE / BSE.
Cipla is a global pharmaceutical company that produces generic and complex APIs and formulations for various therapeutic areas. It has cGMP compliant and approved facilities in India and abroad, and invests in platform technologies and R&D for innovative products.
Cipla is a leading pharmaceutical company with presence in 80+ countries and over 1,500 products across various therapeutic categories. Follow Cipla on LinkedIn to see their updates, events, achievements, and opportunities.
Jan 22, 2024 · Indian generic drugmaker Cipla on Monday reported its third-quarter profit above analysts expectations, boosted by strong performances in North American and domestic markets.
